Menu
About us
Explore about us
Our team
Careers
Solutions
Explore solutions
Bleepa®
Explore Bleepa®
How Bleepa® works
Benefits
Service areas
Patient pathways
Clinical communication
Diagnostic-enhanced advice and guidance
Diagnostic enhanced advice and guidance and ERF payments
Multi-disciplinary team working
Bleepa for cancer MDTs
Private healthcare
Case studies
Feedback Connect
Resources
Explore resources
News feed
Regulatory news (RNS)
Case studies
Resource hub
Safety & security
Digital health and diagnostics record
Investors
Explore investors
Regulatory news (RNS)
Share information
AIM Rule 26
Governance
Advisors
Contact
+44 (0) 20 3997 7634
sales@fbkmed.com
About us
Explore about us
Our team
Careers
Solutions
Explore solutions
Bleepa®
Explore Bleepa®
How Bleepa® works
Benefits
Service areas
Patient pathways
Clinical communication
Diagnostic-enhanced advice and guidance
Diagnostic enhanced advice and guidance and ERF payments
Multi-disciplinary team working
Bleepa for cancer MDTs
Private healthcare
Case studies
Feedback Connect
Resources
Explore resources
News feed
Regulatory news (RNS)
Case studies
Resource hub
Safety & security
Digital health and diagnostics record
Investors
Explore investors
Regulatory news (RNS)
Share information
AIM Rule 26
Governance
Advisors
Contact
+44 (0) 20 3997 7634
sales@fbkmed.com
Contact
Get in
touch
News article
Interim results 2022
Date
10/02/2022
Posted by
FeedbackM_admin
Go Back
